

10

Name of Journal: *World Journal of Gastrointestinal Endoscopy***Manuscript NO:** 57786**Manuscript Type:** REVIEW**Assessment of disease activity in IBD: non-invasive biomarkers and endoscopic scores**

Assessment of Disease Activity in IBD

Bruno Lima Rodrigues, Márcia Carolina Mazzaro, Cristiane Kibune Nagasako, Maria de Lourdes Setsuko Ayrizono, João José Fagundes, Raquel Franco Leal

Match Overview

1	Internet 190 words crawled on 29-Aug-2020 academic.oup.com	3%
2	Internet 46 words crawled on 12-Dec-2019 www.gedii.pt	1%
3	Crossref 44 words Iskandar, H.N.. "Biomarkers in inflammatory bowel disease: current practices and recent advances", <i>Translational R</i>	1%
4	Crossref 36 words Fernando Magro, Joanne Lopes, Paula Borralho, Susana Lopes et al. "Comparison of different histological indexes i	1%
5	Internet 32 words crawled on 01-May-2020 worldwidescience.org	1%
6	Crossref 31 words Aude Marchal Bressenot. "Which evidence for a treat to ... arget strategy in ulcerative colitis?", <i>Best Practice & Rese</i>	<1%

ALL

IMAGES

VIDEOS

36,900 Results

Any time ▾

[Noninvasive Markers of Disease Activity in Inflammatory ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991533>

It is often difficult to assess disease activity in inflammatory bowel disease (IBD). **Noninvasive biomarkers** are a means of quantifying often nebulous symptoms without subjecting patients to endoscopy or **radiation**.

Cited by: 7**Author:** Raluca Vrabie, Sunanda Kane**Publish Year:** 2014

[A Combined Set of Four Serum Inflammatory Biomarkers ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849495>

To test the predictive performances of selected inflammatory **biomarkers**, distributions of serum concentrations of all **biomarkers** were compared between **IBD** patients with binary categorized, composite **IBD endoscopic disease activity**: remission (0) or mild (1) **endoscopic disease activity** vs. moderate (2) or severe (3) **endoscopic disease activity** ...

Cited by: 3**Author:** Arno R. Bourgonje, Julius Z. H. von Mart...**Publish Year:** 2019

[Serum Biomarkers for Inflammatory Bowel Disease - Frontiers](#)

<https://www.frontiersin.org/articles/10.3389/fmed.2020.00123/full> ▾**Introduction**

Diagnosis and Classification ...

Surveillance of Disease Acti



Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a lifelong disease with symptoms that tend to wax and wane and frequent exacerbations. The incidence of IBD is increasing steadily and has become an important public health issue in Western countries and newly industrialized countries (1). Our group reported that 32.9% of patients with CD eventually become disabled by the disease (2). Between 5 and 15% of UC patients required colect...



ALL

IMAGES

VIDEOS

Add the Give with Bing extension >

42,300 Results

Any time ▾

Biomarkers of inflammation in Inflammatory Bowel Disease ...

<https://pubmed.ncbi.nlm.nih.gov/32942275>

Background: **Inflammatory bowel disease (IBD) is a chronically relapsing disease with a continuous need for proactive monitoring to decide appropriate treatments and follow-up strategies.** To date, **gastrointestinal endoscopy with histological examination of biopsies and contrast-enhanced imaging are mandatory techniques for the diagnosis and the activity assessment of IBD.**

Author: Gabriele Dragoni, Tommaso Innocenti, ... **Publish Year:** 2020

How to Grade IBD Disease Activity in Your Daily Practice ...

<https://practicalgastro.com/2018/04/30/how-to...> ▾

**Introduction**

Disease Activity Versus Severit...

Quality of Life

Clinica >

Inflammatory bowel disease (IBD), a progressive and chronic condition, is driven by immunodysregulation of the digestive tract which results in chronic inflammation and disease activity.^{1,2} A significant challenge is how to describe disease activity and severity in a way that is reproducible and actionable. An additional challenge is determining if disease activity and severity is best described using symptoms, colonoscopy findings, or impact of the disease on quality of life. The aim of this review is to discuss accessible measu...

See more on practicalgastro.com

Search Tools

Turn on Hover Translation (开启取词)

激活 Windows

转到“设置”以激活 Windows

Feedback



ALL

IMAGES

VIDEOS

71,900 Results

Any time ▾

Noninvasive Markers of Disease Activity in Inflammatory ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991533>

Inflammatory bowel disease (IBD) is an idiopathic chronic **inflammatory** disorder that encompasses Crohn's **disease** and ulcerative colitis. The 2 **diseases** are quite different in that Crohn's **disease** can involve the entire digestive tract and all 3 mucosal layers, whereas ulcerative colitis affects only the colon and the mucosa.

Cited by: 7

Author: Raluca Vrabie, Sunanda Kane

Publish Year: 2014

Biomarkers of inflammation in Inflammatory Bowel Disease ...

<https://pubmed.ncbi.nlm.nih.gov/32942275>

Background: Inflammatory bowel disease (IBD) is a chronically relapsing disease with a continuous need for proactive monitoring to decide appropriate treatments and follow-up strategies. To date, gastrointestinal endoscopy with histological examination of biopsies and contrast-enhanced imaging are mandatory techniques for the diagnosis and the activity assessment of **IBD**.

Author: Gabriele Dragoni, Tommaso Innocenti... Publish Year: 2020

Faecal markers in the assessment of activity in ...

<https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2036.2002.01196.x>

Faecal platelet-activating factor correlates with the **endoscopic** extent of **bowel** inflammation in ulcerative colitis and Crohn's **disease**. 46 It does not correlate with **disease activity scores** or systemic **inflammatory** markers (CRP and ESR), but, as previously discussed, these reflect **disease activity** ...

Cited by: 137

Author: A. Poullis, R. Foster, T. C. Northfield, M. ...

Publish Year: 2002

Defining the Path Forward for Biomarkers to Address Unmet ...

<https://academic.oup.com/ibdjournal/article/26/10/1451/5894181> ▾

Aug 19, 2020 - Although the content of the **Biomarker** Summit and this special issue of **Inflammatory Bowel Diseases** demonstrate the exciting recent progress in IBD **biomarker** research, there clearly remains a critical, unmet need for validated and precise **biomarkers** to realize the potential for precision medicine for IBD. Here, we summarize the defining features ...

Inflammatory Bowel Disease

Medical Condition

A group of inflammatory conditions of the colon and small intestine



A group of intestinal disorders that cause inflammation of the digestive tract.

- Common (More than 200,000 cases per year in US)
- Often requires lab test or imaging
- Treatments can help manage condition, no known cure
- Can be lifelong

IBD is said to be the result of autoimmune reactions. Inflammatory bowel disease (IBD) presents as Crohn's disease or ulcerative colitis. It may be characterized by diarrhea, abdominal pain and cramping, tiredness, and weight loss. Anti-inflammatory drugs play an important role in the treatment. Surgery is sometimes performed.

Symptoms

Symptoms may vary from mild to severe and include: